Durect Corp DRRX

NAS: DRRX | ISIN: US2666051048   31/05/2024
1,710 USD (+26,67%)
(+26,67%)   31/05/2024

21 mei 2024 · DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis · Persbericht

13 mei 2024 · DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update · Persbericht

7 mei 2024 · DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update · Persbericht

30 april 2024 · DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis · Persbericht

27 maart 2024 · DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update · Persbericht

20 maart 2024 · DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update · Persbericht

4 maart 2024 · DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada · Persbericht

8 februari 2024 · DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference · Persbericht

9 november 2023 · DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update · Persbericht

7 november 2023 · DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality · Persbericht

7 september 2023 · DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis · Persbericht

31 augustus 2023 · DURECT Corporation Announces Presentations in Upcoming Investor Conferences · Persbericht

9 augustus 2023 · DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update · Persbericht

3 augustus 2023 · DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update · Persbericht

20 juli 2023 · DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules · Persbericht

7 juni 2023 · DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis · Persbericht

8 mei 2023 · DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update · Persbericht

2 mei 2023 · DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8 · Persbericht

27 april 2023 · DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis · Persbericht

26 april 2023 · DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference · Persbericht

Mijn selecties